“The [so-called lead compound rule] is in tension with other aspects of obviousness jurisprudence as set forth in decisions of the Federal Circuit itself.” “For a new chemical compound, we apply a two ...
On August 22, 2023, the Federal Circuit affirmed an IPR Final Written Decision holding claims to deuterated derivatives of ruxolitinib unpatentable as obvious and rejected the patentee’s argument that ...
Kapoose Creek Bio Corp. has announced the identification and advancement of two lead compounds with potential in neurology, specifically for indications in neurodegeneration and mental health. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results